|Bid||0.00 x 1100|
|Ask||0.00 x 1000|
|Day's Range||53.47 - 54.87|
|52 Week Range||29.01 - 58.93|
|Beta (3Y Monthly)||1.05|
|PE Ratio (TTM)||26.71|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
Anika Therapeutics received an upgrade to 'Buy' on Monday from TheStreet.com's quantitative service which comes on the heels of its technical breakout last week. In this daily bar chart of ANIK, below, we can see a year-long base pattern with an upside gap/breakout. The On-Balance-Volume (OBV) line turned up to a new high to confirm the buying and so did the Moving Average Convergence Divergence (MACD) oscillator.
Here are four stocks to watch, three of which are moving on strong earnings reports. Anika Therapeutics Inc. (ANIK) popped $11.78, or 29%, to $52.60 on Thursday on 1.3 million shares traded, or about eight times its average volume. The breakaway gap, and continued runup, broke the stock through several layers of lateral resistance, with the next target at the $61 level last reached in early 2018.
Here are four stocks to watch, three of them moving on strong earnings: Anika Therapeutics, Inc . (NASDAQ: ANIK ) popped $11.78, or 28.8%, to $52.60 on Thursday on 1.3 million shares, or about 8x its average ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 25) Akero Therapeutics Inc (NASDAQ: AKRO ) Anika Therapeutics ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 24) Acasti Pharma Inc (NASDAQ: ACST ) Cardiovascular Systems ...
Anika (ANIK) delivered earnings and revenue surprises of 59.52% and 6.69%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
On Anika Therapeutics' (ANIK) second-quarter earnings call, investor focus will be on its progress with the U.S. approval of its orthopedic product Cingal.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alnylam (ALNY) announces new results from the Global Open-Label Extension study of Onpattro at the 2019 Peripheral Nerve Society (PNS) Annual Meeting.
AMAG Pharmaceuticals (AMAG) announces that the FDA has approved Vyleesi to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Vertex's (VRTX) Symdeko gets FDA approval to treat underlying cause of cystic fibrosis in children aged 6-11 years with certain mutations in the CFTR gene.
Anika Therapeutics, Inc. (ANIK) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Billionaire hedge fund managers such as David Abrams, Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and pouring cash into these candidates. Small-cap stocks are overlooked by most investors, brokerage houses, and financial services hubs, while the unlimited research abilities of the […]
Ultragenyx (RARE) and Arcturus Therapeutics expand their existing collaboration to discover and develop mRNA, DNA and siRNA therapeutics for up to 12 rare disease targets.
Arena (ARNA) doses first patient in one of the two pivotal late-stage studies evaluating its pipeline candidate, etrasimod in ulcerative colitis indication.